ScienceBlog.com (blog)Immunotherapy for allergy: novel strategiesScienceBlog.com (blog)In my previous article I summarised the latest ideas for preventing food allergy in early human life, and I gave an honourable mention for treating established food … Continue reading
Next Big FutureCRISPR gene therapy produce rice with 25-31% higher yield …Next Big FutureA team of scientists from Purdue University and the Chinese Academy of Sciences has used CRISPR/Cas9 gene-editing technology to develop a variety of rice … Continue reading
Next Big FutureCRISPR gene therapy produce rice with 25-31% higher yield …Next Big FutureA team of scientists from Purdue University and the Chinese Academy of Sciences has used CRISPR/Cas9 gene-editing technology to develop a variety of rice … Continue reading
|
Longeveron Recruiting for Stem Cell Alzheimer’s Trial in South Florida
PR Newswire (press release) MIAMI, May 23, 2018 /PRNewswire/ — Longeveron LLC, a biopharmaceutical company that develops stem cell therapies for age-related diseases, announced that it is currently recruiting for a Phase 1 clinical trial to evaluate the safety and efficacy of … |
UConn Today |
These CRISPR-modified Crops Don’t Count as GMOs – UConn Today
UConn Today To feed the burgeoning human population, it is vital that the world figures out ways to boost food production. Increasing crop yields through conventional plant … CRISPR plants are on the way—but gene-edited animals face more …Genetic Literacy Project Gene-edited crops rich in omega 3 to be grown in UK for the first timeInfosurhoy |
Rare Disease Report |
CALD Gene Therapy Granted Breakthrough Therapy Designation
Rare Disease Report Supported by positive data from an ongoing Phase 2/3 study, bluebird bio’s Lenti-D has been granted Breakthrough Therapy designation by the US Food and Drug Administration (FDA) for the treatment of patients with cerebral adrenoleukodystrophy (CALD), … |
Rare Disease Report |
CALD Gene Therapy Granted Breakthrough Therapy Designation
Rare Disease Report Supported by positive data from an ongoing Phase 2/3 study, bluebird bio’s Lenti-D has been granted Breakthrough Therapy designation by the US Food and Drug Administration (FDA) for the treatment of patients with cerebral adrenoleukodystrophy (CALD), … |